Toward a pharmacophore for kinase frequent hitters

被引：49

作者：

Aronov, AM ^{[1
]}

Murcko, MA ^{[1
]}

机构：

[1] Vertex Pharmaceut Inc, Cambridge, MA 02139 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 23期

关键词：

D O I：

10.1021/jm049793g

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Small molecule protein kinase inhibitors are widely employed as biological reagents and as leads in the design of drugs for a variety of diseases. One of the hardest challenges in kinase inhibitor design is achieving target selectivity. By utilizing X-ray structural information for four promiscuous inhibitors, we propose a five-point pharmacophore for kinase frequent hitters, demonstrate its ability to discriminate between frequent hitters and selective ligands, and suggest a strategy for selective inhibitor design.

引用

收藏

页码：5616 / 5619

页数：4

相关论文

共 20 条

[1] The properties of known drugs .1. Molecular frameworks [J].

Bemis, GW ;

Murcko, MA .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) :2887-2893

[2] Protein kinase a in complex with rho-kinase inhibitors Y-27632, fasudil, and H-1152P: Structural basis of selectivity [J].

Breitenlechner, C ;

Gassel, M ;

Hidaka, H ;

Kinzel, V ;

Huber, R ;

Engh, RA ;

Bossemeyer, D .

STRUCTURE, 2003, 11 (12) :1595-1607

[3] Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].

Capdeville, R ;

Buchdunger, E ;

Zimmermann, J ;

Matter, A .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502

[4] Issues and progress with protein kinase inhibitors for cancer treatment [J].

Dancey, J ;

Sausville, EA .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (04) :296-313

[5] Kinases, homology models, and high throughput docking [J].

Diller, DJ ;

Li, RX .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (22) :4638-4647

[6] METHODS FOR DRUG DISCOVERY - DEVELOPMENT OF POTENT, SELECTIVE, ORALLY EFFECTIVE CHOLECYSTOKININ ANTAGONISTS [J].

EVANS, BE ;

RITTLE, KE ;

BOCK, MG ;

DIPARDO, RM ;

FREIDINGER, RM ;

WHITTER, WL ;

LUNDELL, GF ;

VEBER, DF ;

ANDERSON, PS ;

CHANG, RSL ;

LOTTI, VJ ;

CERINO, DJ ;

CHEN, TB ;

KLING, PJ ;

KUNKEL, KA ;

SPRINGER, JP ;

HIRSHFIELD, J .

JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (12) :2235-2246

[7] CDK versus GSK-3 inhibition: a purple haze no longer? [J].

Fischer, PM .

CHEMISTRY & BIOLOGY, 2003, 10 (12) :1144-1146

[8] An efficient proteomics method to identify the cellular targets of protein kinase inhibitors [J].

Godl, K ;

Wissing, J ;

Kurtenbach, A ;

Habenberger, P ;

Blencke, S ;

Gutbrod, H ;

Salassidis, K ;

Stein-Gerlach, M ;

Missio, A ;

Cotten, M ;

Daub, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (26) :15434-15439

[9] Privileged molecules for protein binding identified from NMR-based screening [J].

Hajduk, PJ ;

Bures, M ;

Praestgaard, J ;

Fesik, SW .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (18) :3443-3447

[10]

Klabunde T, 2002, CHEMBIOCHEM, V3, P929, DOI 10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO